The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania donovani both in vitro and in vivo. Twice-daily oral dosing of delamanid at 30 mg kg-1 for 5 days resulted in sterile cures in a mouse model of VL. Treatment with lower doses revealed a U-shaped (hormetic) dose-response curve with greater parasite suppression at 1 mg kg-1 than at 3 mg kg-1 (5 or 10 day dosing). Dosing delamanid for 10 days confirmed the hormetic dose-response and improved the efficacy at all doses investigated. Mechanistic studies reveal that delamanid is rapidly metabolised by parasites via an enzyme, distinct from the nitroreductase that activates fexinidazole. Delamanid has the potential to be repurposed as a much-needed oral therapy for VL. DOI: http://dx.doi.org/10.7554/eLife.09744.001

[1]  A. Fairlamb,et al.  Trypanothione biosynthesis in Leishmania major. , 2005, Molecular and biochemical parasitology.

[2]  C. Barry,et al.  The mechanism of action of PA-824 , 2009, Communicative & integrative biology.

[3]  M. Katze,et al.  Drug repurposing: a better approach for infectious disease drug discovery? , 2013, Current Opinion in Immunology.

[4]  Irene Hallyburton,et al.  Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis , 2010, Biochemical pharmacology.

[5]  S. Norval,et al.  The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis , 2012, Science Translational Medicine.

[6]  Jeffrey Aubé,et al.  Drug repurposing and the medicinal chemist. , 2012, ACS medicinal chemistry letters.

[7]  J. Peters.  Polypharmacology - foe or friend? , 2013, Journal of medicinal chemistry.

[8]  S. Norval,et al.  The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis , 2013, Antimicrobial Agents and Chemotherapy.

[9]  Jakir Pinjari,et al.  In vitro metabolism, disposition, preclinical pharmacokinetics and prediction of human pharmacokinetics of DNDI-VL-2098, a potential oral treatment for Visceral Leishmaniasis. , 2014, European Journal of Pharmaceutical Sciences.

[10]  J. Norton,et al.  Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Nicola J. Ryan,et al.  Delamanid: First Global Approval , 2014, Drugs.

[12]  J M FAVERGE,et al.  [Statistical treatment of experimental data]. , 1951, Journal de physiologie.

[13]  Vicki Stone,et al.  An in vitro assessment of panel of engineered nanomaterials using a human renal cell line: cytotoxicity, pro-inflammatory response, oxidative stress and genotoxicity , 2013, BMC Nephrology.

[14]  S. Sundar,et al.  Cost-Effectiveness Analysis of Combination Therapies for Visceral Leishmaniasis in the Indian Subcontinent , 2010, PLoS neglected tropical diseases.

[15]  Edward H. Kerns,et al.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.

[16]  J. Cano,et al.  Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.

[17]  D. Bradley,et al.  Regulation of Leishmania populations within the host. I. the variable course of Leishmania donovani infections in mice. , 1977, Clinical and experimental immunology.

[18]  L. Cuevas,et al.  Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co‐infection in northwest Ethiopia , 2010, Tropical medicine & international health : TM & IH.

[19]  M. Matsumoto,et al.  OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In Mice , 2006, PLoS medicine.

[20]  Simon Croft,et al.  Kinetoplastids: related protozoan pathogens, different diseases. , 2008, The Journal of clinical investigation.

[21]  M. Boelaert,et al.  Infection rates with Leishmania donovani and Mycobacterium tuberculosis in a village in eastern Sudan , 2004, Tropical medicine & international health : TM & IH.

[22]  Edward J Calabrese,et al.  Hormesis: the dose-response revolution. , 2003, Annual review of pharmacology and toxicology.

[23]  Mohammad Wahid Ansari,et al.  The legal status of in vitro embryos , 2014 .

[24]  M. Matsumoto,et al.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles. , 2006, Journal of medicinal chemistry.

[25]  K. Read,et al.  Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African Trypanosomiasis , 2010, Antimicrobial Agents and Chemotherapy.

[26]  Noriyuki Koyama,et al.  Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo , 2015, Drug Metabolism and Disposition.

[27]  S. Beverley,et al.  An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. , 2003, Molecular and biochemical parasitology.

[28]  L. Scott,et al.  Delamanid: A Review of Its Use in Patients with Multidrug-Resistant Tuberculosis , 2014, Drugs.

[29]  Liang-Shang Gan,et al.  Plasma protein binding: from discovery to development. , 2013, Journal of pharmaceutical sciences.

[30]  A. Fairlamb,et al.  Refinement of techniques for the propagation of Leishmania donovani in hamsters. , 2006, Acta Tropica.

[31]  C. Landersdorfer,et al.  PK/PD models in antibacterial development. , 2013, Current opinion in microbiology.

[32]  Christopher T. Walsh,et al.  Antibiotics for Emerging Pathogens , 2009, Science.

[33]  K. Andrews,et al.  Drug repurposing and human parasitic protozoan diseases , 2014, International journal for parasitology. Drugs and drug resistance.

[34]  B. Hall,et al.  Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites* , 2011, The Journal of Biological Chemistry.

[35]  V. Yardley,et al.  Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. , 2015, The Journal of antimicrobial chemotherapy.

[36]  S. Wyllie,et al.  Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects , 2014, Trends in parasitology.

[37]  E. Calabrese,et al.  Applications of hormesis in toxicology, risk assessment and chemotherapeutics. , 2002, Trends in pharmacological sciences.

[38]  Natalia Novac,et al.  Challenges and opportunities of drug repositioning. , 2013, Trends in pharmacological sciences.

[39]  Pilho Kim,et al.  PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.

[40]  Hugh D. Young,et al.  Statistical Treatment of Experimental Data. , 1963 .

[41]  K. Umehara,et al.  Metabolic Mechanism of Delamanid, a New Anti-Tuberculosis Drug, in Human Plasma , 2015, Drug Metabolism and Disposition.

[42]  V. Yardley,et al.  Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. , 2016, Journal of medicinal chemistry.

[43]  R. López-Vélez,et al.  The Relationship between Leishmaniasis and AIDS: the Second 10 Years , 2008, Clinical Microbiology Reviews.

[44]  A. Fairlamb,et al.  Assessing the Essentiality of Leishmania donovani Nitroreductase and Its Role in Nitro Drug Activation , 2012, Antimicrobial Agents and Chemotherapy.

[45]  David J. Newman,et al.  New horizons for old drugs and drug leads. , 2014, Journal of natural products.